Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and ...

Bariatric surgery reduces the progression to decompensated cirrhosis and the risk for major adverse liver outcomes, such as ...

Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.

A modeling study predicts a substantial rise in MASLD prevalence and associated liver-related complications in the United ...

Metabolic surgery significantly lowered risk for major adverse liver outcomes vs. nonsurgical management among patients with ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Rye Single Barrels are uncut, unfiltered, malt-forward whiskeys that were inspired by the distillery’s first experimental ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...